SAS Output

22-SEP-2017 18:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9365 777 378 172 66 15 BREAST
        9365 777 378 172 66 15  
 
  2 Y 2 Chemo and Endocrine Therapy 2529 257 128 57 17 5  
      3 Endocrine Therapy Alone 2518 258 124 55 20 5  
        5047 515 252 112 37 10  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 677 213 106 45 18 5 BREAST
      2 Blinded drug + Endocrine 679 217 106 53 23 2  
        1356 430 212 98 41 7  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization Surgery 2 1 1 1 1 1 SURV
      2 Randomization Non-surgical M 1 1 1 0 0 0  
      3 Patient Choice Surgery 33 20 11 4 0 0  
      4 Patient Choice Non-surgical M 74 44 29 15 5 1  
        110 66 42 20 6 2  
 
S1400I-Non-Match: Nivo + Ipi vs Nivo 1 Y 1 Nivolumab + Ipilimumab 112 60 24 11 1 0 LUNG
      2 Nivolumab 117 62 28 13 7 1  
        229 122 52 24 8 1  
 
S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 2 Y 2 FDA approved regimen 678 488 243 118 21 1 MELAN
      3 MK-3475 (Pembrolizumab) 667 484 243 110 20 0  
        1345 972 486 228 41 1  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 311 311 178 84 22 6 CCD
      2 Site randomized: Control 179 179 152 81 29 5  
      3 SiteRand Int Risk: CSF 229 229 167 103 41 15  
      4 SiteRand Int Risk: No CSF 176 176 152 92 39 7  
        895 895 649 360 131 33  
 
S1417CD-Colorectal, Cost Cohort Study 1 Y 1 Observation 106 96 74 41 14 4 CCD
        106 96 74 41 14 4  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 81 81 70 43 20 4 BREAST
        81 81 70 43 20 4  
 
  2 Y 2 Observation 32 32 30 16 8 0  
      3 MK-3475 (Pembrolizumab) 34 34 31 18 7 2  
        66 66 61 34 15 2  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y   1 0 0 0 0 0 SURV
        1 0 0 0 0 0  
 
  2 Y   1 0 0 0 0 0  
        1 0 0 0 0 0  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 10 10 9 5 2 0 GU
      2 Tokyo-172 BCG 11 11 11 8 4 2  
      3 Prime + Tokyo-172 BCG 11 11 10 8 2 2  
        32 32 30 21 8 4  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 405 143 69 45 10 4 PREV
        405 143 69 45 10 4  
 
  1 Y 1 Blinded drug 44 18 11 2 1 0  
      2 Blinded drug 36 11 2 0 0 0  
      3 Blinded drug 35 11 2 0 0 0  
      4 Blinded drug 46 20 13 6 3 0  
        161 60 28 8 4 0  
 

22-SEP-2017 18:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Open Studies with No Registrations
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol regtype: 1
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol regtype: 2